Bevacizumab, Radiotherapy and Temozolomide Safety study in resected and irresectable primary GBM patients.

Trial Profile

Bevacizumab, Radiotherapy and Temozolomide Safety study in resected and irresectable primary GBM patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Biomarker
  • Acronyms BERTES
  • Most Recent Events

    • 30 Jan 2016 Status changed from recruiting to completed.
    • 12 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top